Filing Overview
TriSalus Life Sciences, Inc. filed a Form 8-K dated January 24, 2024, under Item 5.02. The filing reports a compensatory equity award to the Company’s Chief Financial Officer, Sean Murphy.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Change and Compensation Award
- On January 24, 2024, the Board granted Mr. Murphy an option to purchase 125,000 shares of common stock.
- The award was granted under the Company’s 2023 Equity Incentive Plan in recognition of Mr. Murphy’s performance in 2023.
- The exercise price is $9.28 per share.
- Vesting is 25% on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, subject to continued service.
Guidance, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. The option award may result in future stock-based compensation expense and potential dilution if exercised, but the filing does not quantify either impact.
Investor Verification Items
- Verify the 125,000-share option grant, $9.28 exercise price, and vesting schedule.
- Review subsequent filings for the award’s fair value, stock-based compensation expense, and potential dilution.
- Confirm whether any additional compensation arrangements or equity awards were disclosed in related filings.